• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of new molecular target therapy based on anti-angiogenesis in ovarian cancer

Research Project

Project/Area Number 15591747
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Obstetrics and gynecology
Research InstitutionKagawa Prefectural College of Health Sciences (2004-2005)
Shimane Medical University (2003)

Principal Investigator

HATA Kohkichi  Kagawa Prefectural College of Health Sciences, Faculty of Health Science, Professor, 保健医療学部, 教授 (70180875)

Project Period (FY) 2003 – 2005
Project Status Completed (Fiscal Year 2005)
Budget Amount *help
¥3,300,000 (Direct Cost: ¥3,300,000)
Fiscal Year 2005: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 2004: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 2003: ¥1,400,000 (Direct Cost: ¥1,400,000)
Keywordsepithelial ovarian cancer / Angiopoietin-1 / Angiopoietin-2 / in situ hybridization / mRNA expression / Tie2 / immunohistochemistry / VEGF / real-time quantitative RT-PCR / angiogenesis / prognosis / RT-real time PCR / Taxol / antivascular therapy
Research Abstract

The recent discovery of angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) has provided novel and important insights into the molecular mechanisms of blood vessel formation. Ang-1 helps to maintain and stabilize mature vessels by promoting interaction between endothelial cells and surrounding support cells, e.g., pericytes. Ang-2 is expressed at sites of vascular remodeling and is believed to antagonize the stabilizing action of Ang-1. In the presence of vascular endothelial growth factor (VEGF), vessel destabilization by Ang-2 has been hypothesized to induce an angiogenic response. However, in the absence of VEGF, Ang-2 leads to vessel regression. Although the exact role of the angiopoietin/Tie2 system remains enigmatic, the available evidence indicates that the angiopoietin/Tie2 system in the presence of VEGF is important for the initiation of angiogenesis and for vascular sprouting in tumor.
The role of angiopoietin/Tie2 system with VEGF in epithelial ovarian cancer has been revealed by molecular biological analysis. A new insight to understand the biology of epithelial ovarian cancer might lead to development of a new molecular target therapy for epithelial ovarian cancer.

Report

(4 results)
  • 2005 Annual Research Report   Final Research Report Summary
  • 2004 Annual Research Report
  • 2003 Annual Research Report
  • Research Products

    (17 results)

All 2006 2005 2004 2003 Other

All Journal Article (8 results) Book (3 results) Publications (6 results)

  • [Journal Article] Expression of Angiopoietin-1, Angiopoietin-2, and Tie2 in Normal Ovary with Corpus Luteum and in Ovarian Carcinoma2006

    • Author(s)
      Kohkichi Hata
    • Journal Title

      Handbook of Immunohistochemistry and in situ Hybridization of Human Carcinoma Vol.4

      Pages: 519-522

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2005 Final Research Report Summary
  • [Journal Article] 子宮内膜症・子宮腺筋症の超音波診断2005

    • Author(s)
      秦 幸吉, 秦 利之
    • Journal Title

      画像診断 2・1

      Pages: 147-152

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2005 Annual Research Report 2005 Final Research Report Summary
  • [Journal Article] 臨床医のための超音波診断アトラス 産科・婦人科 卵巣・卵管2005

    • Author(s)
      秦 幸吉
    • Journal Title

      綜合臨床 54・増刊号

      Pages: 1229-1240

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2005 Annual Research Report 2005 Final Research Report Summary
  • [Journal Article] 婦人科腫瘍の超音波診断法2005

    • Author(s)
      秦 幸吉
    • Journal Title

      日本産科婦人科学会香川地方部会雑誌 7・1

      Pages: 7-19

    • NAID

      120007011478

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2005 Annual Research Report 2005 Final Research Report Summary
  • [Journal Article] Evaluation of the antiangiogenic effect of taxol in a human epithelial ovarian cancer2004

    • Author(s)
      Hata K, Osaki M, Dhar DK, Nakayama K, Fujiwaki R, Ito M, Nagasue N, Miyazaki K
    • Journal Title

      Cancer Chemotherapy Pharmacology 53・1

      Pages: 68-74

    • Related Report
      2004 Annual Research Report
  • [Journal Article] Expression of the angiopoietin-1, angiopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer2004

    • Author(s)
      Hata K, Nakayama K, Fujiwaki R, Katabuchi H, Okamura H, Miyazaki K
    • Journal Title

      Gynecologic Oncology 90・6

      Pages: 215-222

    • Related Report
      2004 Annual Research Report
  • [Journal Article] Allelic loss at 19q12 and Xq11-12 predict an adverse clinical outcome in patients with mucinous ovarian tumors of low malignant potential2004

    • Author(s)
      Nakayama K, Takebayashi Y, Hata K, Fujiwaki R, Iida K, Fukumoto M, Miyazaki K
    • Journal Title

      British Journal of Cancer 90・6

      Pages: 1204-1210

    • Related Report
      2004 Annual Research Report
  • [Journal Article] Adenocarcinoma in situ coexisting with carcinoma in situ of the cervix during pregnancy2003

    • Author(s)
      Nakaishi M, Fujiwaki R, Hata K, Makihara K, Yamane Y, Miyazaki K
    • Journal Title

      Archieves of Gynecology and Obstetrics 270・2

      Pages: 116-118

    • Related Report
      2004 Annual Research Report
  • [Book] Handbook of Immunohistochemistry and in situ Hybridization of Human Carcinoma2006

    • Author(s)
      Kohkichi Hata
    • Publisher
      Expression of Angiopoietin-1, Angiopoietin-2, and Tie2 in Normal Ovary with Corpus Luteum and in Ovarian Carcinoma(出版予定)
    • Related Report
      2005 Annual Research Report
  • [Book] 超音波医学TEXT 産婦人科超音波医学2004

    • Author(s)
      岡井 崇, 名取道也, 秦 幸吉
    • Total Pages
      188
    • Publisher
      医歯薬出版株式会社
    • Related Report
      2004 Annual Research Report
  • [Book] Handbook of Immunohistochemistry and in situ Hybridization of Human Carcinoma

    • Author(s)
      Kohkichi Hata
    • Publisher
      (出版予定)
    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2005 Final Research Report Summary
  • [Publications] Hata_K, Osaki M, Kanasaki H, Nakayama K, Fujiwaki R, Ito H, Miyazaki K: "Induction of thymidine phosphorylase expression by Taxol does not enhance Furtulon sensitivity in a cisplatin-resistant human ovarian carcinoma cell line"Anticancer Research. 23・2. 1525-1531 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Hata K, Dhar DK, Kanasaki H, Nakayama K, Fujiwaki R, Katabuchi H, Okamura H, Nagasue N, Miyazaki K: "Serum endostatin levels in patients with epithelial ovarian cancer"Anticancer Research. 23・2. 1907-1912 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Hata K, Osaki M, Kanasaki H, Nakayama K, Fujiwaki R, Ito H, Miyazaki K: "Induction of thymidine phosphorylase expression and enhancement of Furtulon sensitivity by Taxol in a human ovarian carcinoma cell line"Anticancer Research. 23・3. 2665-2669 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Nakayama K, Takebayashi Y, Nakayama S, Hata_K, Fujiwaki R, Fukumoto M, Miyazaki K: "Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin"Cancer Letter. 192・2. 227-235 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Nakayama S, Nakayama K, Takebayashi Y, Hata_K, Fujiwaki R, Fukumoto M, Miyazaki K: "Allelotypes as potential prognostic markers in ovarian carcinoma treated with cisplatin-based chemotherapy"International Journal of Molecular Medicine. 11・5. 621-625 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Hata K, Osaki M, Dhar DK, Nakayama K, Fujiwaki R, Ito M, Nagasue N, Miyazaki K: "Evaluation of the antiangiogenic effect of taxol in a human epithelial ovarian cancer"Cancer Chemotherapy Pharmacology. 53・1. 68-74 (2004)

    • Related Report
      2003 Annual Research Report

URL: 

Published: 2003-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi